Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Beth on +44 1494 818 013 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Beth Horsley
MDD EXEC Team Leader
+44 1494 818 013

Zenopa were extremely helpful in finding positions that suited my skill-set and experience. Zenopa has as friendly yet professional approach which helped them identify the role and level I was aspirin...
David, 2013

Stryker completes Concentric Medical takeover

4 October 2011 00:00 in Medical Company Restructures

Stryker has announced the completion of its takeover of Concentric Medical, a leading developer of therapies for acute ischemic stroke.

Originally announced at the end of August 2011, the deal has seen Stryker pay $135 million (87.73 million pounds) to take control of Concentric, which is based in California and has been operating since 1999.

The newly-acquired firm is known for its offering of minimally invasive devices for the removal of thrombus in patients affected by stroke, such as the Trevo Retriever clot removal system, which is currently undergoing clinical trials.

Stryker expects the acquisition to expand its presence in the European, US and Japanese acute ischemic stroke markets, while giving it access to a workforce with proven expertise in this area.

The deal has also been forecast as having a neutral effect in the firm's earnings per share figure for 2011.

Stephen MacMillan, chairman, president and chief executive officer of Stryker, said: "We are further broadening our commitment to advancing care within the interventional neurovascular space by bringing innovative treatment options to the large and underserved ischemic stroke population."ADNFCR-8000103-ID-800747948-ADNFCR

Other news stories from 04/10/2011

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd